Alyftrek 10-50-125 MG tablet 14S
Ended Awarded
- Contract number
- SPE2DR26FCRG0
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $20,995
Award facts
- Contract value 100% obligated
- $20,995.46 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $20,995.46 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for ALYFTREK 10-50-125 mg tablets. The award was issued on November 4, 2025, with an ultimate completion date of November 5, 2025, under a firm fixed-price contract type with no set-aside designation. This delivery order represents one of numerous orders placed with DMS Pharmaceutical Group through the company's role as a critical supplier within the federal pharmaceutical supply chain, particularly for Department of Defense healthcare operations.
DMS Pharmaceutical Group holds a single-award Indefinite Delivery Contract under the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy designed to support recurring medical supply needs of military healthcare facilities worldwide. The underlying IDC, designated SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. The current delivery order for ALYFTREK tablets falls within the broader scope of the PPV-G GEN V contract, which authorizes DLA to procure a comprehensive range of pharmaceutical products including branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support Department of Defense military medical operations globally.
Quick answers
Who was awarded contract SPE2DR26FCRG0?
SPE2DR26FCRG0 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 4, 2025.
How much is contract SPE2DR26FCRG0 worth?
The government has obligated $20,995 on SPE2DR26FCRG0.
Is contract SPE2DR26FCRG0 an order under another contract?
Yes. SPE2DR26FCRG0 is a delivery order under SPE2DR25D9168, an indefinite delivery contract.
Was contract SPE2DR26FCRG0 competed?
The extent of competition for SPE2DR26FCRG0 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award